november AG
november AG english
november AG shows dynamic growth
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG shows dynamic growth
Erlangen, November 14, 2001. Listed at the Neuer Markt segment of the German
stock exchange, november AG continues its course of dynamic development and
growth. In the first nine months of this year, the Erlangen-based biotech
company was able to increase revenues to TDM 5,376, which amounts to an increase
of about 180 percent compared to last year’s figures (TDM 1,904). The positive
development of the subsidiary PEQLAB Biotechnologie GmbH significantly
contributed to this success. PEQLAB had been acquired in the previous year and
was first included into the consolidation group of november AG on 31-10-2000.
The number of employees was raised to 87 compared to 54 in last year’s reference
period. According to plan, expenditures for research and development were
increased significantly, as well, from TDM 4,283 last year to TDM 7,446 in this
year. The consolidated net loss of TDM 7,925, which is higher compared to last
year (TDM 5,387), resulted mostly from these expenditures and underlines the
substantial efforts of the company to drive the projects in all business areas
to marketability as quickly as possible. Supported by the expansion of
cooperations, key steps have been taken during the third quarter in the
important fields of product development (miniature lab for molecular diagnosis),
the beginning of pre-clinical testing (molecular therapy), and market
introduction (product and brand protection with IDENT technology). Biological
labeling has already reached a development stage in which it will be
commercialized. The consolidated net loss which is within the scope of the plan
of the company will be carried forward and raises the accumulated deficit to TDM
24,223 on September 30, 2001 (12-31-2000: TDM 16,298). Net earnings per share
(EPS and DVFA/SG) were DM -1.20 (previous year’s period: DM -0.95). The overall
liquidity of november AG amounting to approx. 50.3 million DM on 9-30-2001 (12-
31-2000: 68.6 million DM) should still be rated as excellent, even after the
repayment of silent partnerships plus corresponding final payments amounting to
about 5.6 million DM during the reporting period. Thus, reaching the break-even
according to plan is fully secured without the need for external funding.
Contact: Christian Fenner, Investor Relations
Tel. +49 (0)9131/75088-870, Fax +49(0)9131/75088-899, fenner@november.de
end of ad-hoc-announcement (c)DGAP 14.11.2001
——————————————————————————–
WKN: 676290; Index:
Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, München, Hannover und Stuttgart
140800 Nov 01
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden